Seeking Alpha

The FDA has approved Exelixis' (EXEL) cabozantinib thyroid cancer drug. Shares are halted....

The FDA has approved Exelixis' (EXEL) cabozantinib thyroid cancer drug. Shares are halted. (previous)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector